X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (332) 332
Publication (27) 27
Newspaper Article (24) 24
Newsletter (17) 17
Book Review (11) 11
Book Chapter (4) 4
Conference Proceeding (3) 3
Magazine Article (3) 3
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dalbavancin (318) 318
humans (149) 149
index medicus (133) 133
pharmacology & pharmacy (106) 106
teicoplanin - analogs & derivatives (102) 102
infectious diseases (93) 93
microbiology (89) 89
once-weekly dalbavancin (86) 86
anti-bacterial agents - therapeutic use (81) 81
resistant staphylococcus-aureus (79) 79
vancomycin (79) 79
anti-bacterial agents - pharmacology (76) 76
oritavancin (67) 67
antibiotics (65) 65
soft-tissue infections (63) 63
microbial sensitivity tests (55) 55
teicoplanin - pharmacology (55) 55
complicated skin (54) 54
skin-structure infections (52) 52
health aspects (51) 51
telavancin (51) 51
in-vitro activity (49) 49
skin (49) 49
staphylococcus aureus (47) 47
daptomycin (46) 46
care and treatment (43) 43
acute bacterial skin (42) 42
linezolid (40) 40
research (40) 40
gram-positive bacterial infections - drug therapy (39) 39
teicoplanin - therapeutic use (39) 39
glycopeptide (38) 38
drug resistance in microorganisms (37) 37
drug therapy (37) 37
pharmaceutical industry (37) 37
pharmacokinetics (36) 36
animals (35) 35
anti-bacterial agents - adverse effects (35) 35
infections (35) 35
dosage and administration (34) 34
lipoglycopeptide (34) 34
staphylococcus aureus infections (34) 34
therapy (33) 33
gram-positive bacteria (32) 32
infection (32) 32
internal medicine (31) 31
skin diseases, bacterial - drug therapy (31) 31
anti-bacterial agents - pharmacokinetics (30) 30
ceftaroline (30) 30
in-vitro (30) 30
mrsa (30) 30
gram-positive bacteria - drug effects (29) 29
male (29) 29
teicoplanin - adverse effects (29) 29
glycopeptides (28) 28
methicillin-resistant staphylococcus aureus (28) 28
anti-bacterial agents - administration & dosage (26) 26
drug resistance (26) 26
drug resistance, bacterial (26) 26
staphylococcal infections - drug therapy (26) 26
antibacterial agents (25) 25
gram-positive bacterial infections - microbiology (25) 25
infectious disease (25) 25
staphylococcus infections (25) 25
tigecycline (25) 25
double-blind (24) 24
female (24) 24
gram-positive pathogens (24) 24
medicine & public health (23) 23
methicillin (23) 23
dermatology (22) 22
lipoglycopeptides (22) 22
medical research (22) 22
medicine, experimental (22) 22
staphylococcus aureus - drug effects (22) 22
staphylococcus-aureus (22) 22
teicoplanin (22) 22
teicoplanin - pharmacokinetics (22) 22
vancomycin - pharmacology (22) 22
resistance (21) 21
single-dose oritavancin (21) 21
tedizolid (21) 21
antimicrobial agents (20) 20
drug resistance, multiple, bacterial (20) 20
glycopeptides - therapeutic use (20) 20
methicillin-resistant staphylococcus aureus - drug effects (20) 20
spectrum (20) 20
staphylococcal infections - microbiology (20) 20
susceptibility (20) 20
surveillance (19) 19
teicoplanin - administration & dosage (19) 19
tirofiban (19) 19
treprostinil (19) 19
usage (19) 19
anti-bacterial agents - chemistry (18) 18
securities industry (18) 18
soft tissue infections - drug therapy (18) 18
trademarks (18) 18
vancomycin resistance (18) 18
adult (17) 17
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (356) 356
Spanish (17) 17
German (2) 2
Turkish (2) 2
Chinese (1) 1
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 01/2017, Volume 35, Issue 35, pp. 22 - 27
Dalbavancin is a new lipoglycopeptide antibiotic whose structure influences its pharmacokinetic profile. It is not absorbed after oral administration and is... 
Pharmacokinetics | Pharmacokinetics/pharmacodynamics | Dalbavancin
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 11/2019, Volume 53, Issue 11, pp. 1093 - 1101
Background: Although dalbavancin’s (DBV’s) long half-life and one-time dosing strategy confer ideal administration in the ambulatory setting, the optimal role... 
ABSSSI | emergency department | dalbavancin | telehealth | cellulitis | ACUTE BACTERIAL SKIN | THERAPY | ONCE-WEEKLY DALBAVANCIN | PHARMACOLOGY & PHARMACY
Journal Article
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 01/2017, Volume 35, Issue 35, pp. 15 - 21
Dalbavancin is a semisynthetic lipoglycopeptide approved for the treatment of acute skin and soft tissue infections due to Gram-positive microorganisms... 
Breakpoints | Dalbavancin | Lipoglycopeptides | Subrogate value
Journal Article
Current Opinion in Infectious Diseases, ISSN 0951-7375, 04/2019, Volume 32, Issue 2, pp. 123 - 129
PURPOSE OF REVIEWAn increase of skin and soft tissue infections involving Staphylococcus aureus has been reported in community and hospital settings.... 
INFECTIOUS DISEASES | skin and soft tissue infections | SAFETY | ONCE-WEEKLY DALBAVANCIN | methicillin-resistant Staphylococcus aureus | TEDIZOLID PHOSPHATE | RESISTANT STAPHYLOCOCCUS-AUREUS | dalbavancin | COMPLICATED SKIN | ACUTE BACTERIAL SKIN | VANCOMYCIN | PHARMACOKINETICS | tedizolid | SINGLE-DOSE ORITAVANCIN | IN-VITRO ACTIVITY
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2018, Volume 67, Issue 5, pp. 795 - 798
Abstract The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were... 
Gram-positive infection | Endocarditis | Dalbavancin | INFECTIOUS DISEASES | MANAGEMENT | RANDOMIZED CLINICAL-TRIAL | GUIDELINES | STAPHYLOCOCCUS-AUREUS MRSA | MICROBIOLOGY | endocarditis | SKIN | IMMUNOLOGY | dalbavancin | SOCIETY
Journal Article
Drugs, ISSN 0012-6667, 5/2010, Volume 70, Issue 7, pp. 859 - 886
Dalbavancin, oritavancin and telavancin are semisynthetic lipoglycopeptides that demonstrate promise for the treatment of patients with infections caused by... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Bacterial-infections, treatment | Oritavancin, general | Research-and- development | Glycoproteins, therapeutic use | Telavancin, general | Antimicrobial-resistance | Dalbavancin, general | Skin-and-soft-tissue-infections, treatment | SOFT-TISSUE INFECTIONS | GLYCOPEPTIDE ANTIBIOTICS | GRAM-POSITIVE BACTERIA | CELL-WALL SYNTHESIS | SKIN-STRUCTURE INFECTIONS | ONCE-WEEKLY DALBAVANCIN | ENTEROCOCCUS-FAECIUM | PHARMACOLOGY & PHARMACY | TOXICOLOGY | RESISTANT STAPHYLOCOCCUS-AUREUS | IN-VITRO ACTIVITY | COMPLICATED SKIN | Humans | Glycopeptides - chemistry | Teicoplanin - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Interactions | Anti-Bacterial Agents - chemistry | Gram-Positive Bacterial Infections - microbiology | Anti-Bacterial Agents - adverse effects | Molecular Structure | Glycopeptides - pharmacokinetics | Teicoplanin - pharmacokinetics | Teicoplanin - analogs & derivatives | Aminoglycosides - pharmacokinetics | Teicoplanin - chemistry | Aminoglycosides - chemistry | Treatment Outcome | Clinical Trials as Topic | Glycopeptides - adverse effects | Glycopeptides - therapeutic use | Teicoplanin - adverse effects | Animals | Anti-Bacterial Agents - pharmacokinetics | Aminoglycosides - adverse effects | Gram-Positive Bacterial Infections - drug therapy | Drug Resistance, Multiple, Bacterial - drug effects | Aminoglycosides - therapeutic use | Complications and side effects | Gram-positive bacterial infections | Peptides | Dosage and administration | Research | Comparative analysis | Drug therapy | Antibacterial agents | Health aspects
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 08/2019
Dalbavancin is a glycopeptide antibiotic with a long half-life, recently marketed in Europe for skin and soft tissue infections (SSTI), but real-life use is... 
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 08/2019
Dalbavancin is a lipoglycopeptide antibiotic active against gram positive organisms with unique weekly dosing. This retrospective study included 37 patients... 
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 01/2017, Volume 35, Issue 35, pp. 28 - 32
Multiresistant Gram-positive infections continue to pose a major clinical challenge and the development of new antibiotics is always desirable. Dalbavancin is... 
Lipoglycopeptide | In vivo | Animal models | Dalbavancin
Journal Article
Open Forum Infectious Diseases, ISSN 2328-8957, 01/2019, Volume 6, Issue 1, p. ofy331
Background Osteomyelitis is a challenging infection that can involve 4-6 weeks of intravenous (IV) antibiotics. Dalbavancin, approved for acute bacterial skin... 
osteomyelitis | gram-positive | dalbavancin | INFECTIOUS DISEASES | AMERICA | GUIDELINES | ONCE-WEEKLY DALBAVANCIN | MICROBIOLOGY | IMMUNOLOGY | THERAPY | ANTIBIOTIC-TREATMENT | SKIN | BONE | INFECTIOUS-DISEASES SOCIETY
Journal Article
International Journal of Antimicrobial Agents, ISSN 0924-8579, 04/2018, Volume 51, Issue 4, pp. 571 - 577
Dalbavancin is a lipoglycopeptide with a very prolonged half-life enabling treatment with a single intravenous administration that has been approved to treat... 
Gram-positive infection | Skin and soft-tissue infection | Dalbavancin | SOFT-TISSUE INFECTIONS | INFECTIOUS DISEASES | MANAGEMENT | ONCE-WEEKLY DALBAVANCIN | MICROBIOLOGY | RESISTANT STAPHYLOCOCCUS-AUREUS | COMPLICATED SKIN | ACUTE BACTERIAL SKIN | SKIN-STRUCTURE INFECTIONS | PARENTERAL ANTIMICROBIAL THERAPY | PHARMACOLOGY & PHARMACY | CONVENTIONAL THERAPY | CLINICAL-OUTCOMES | Humans | Middle Aged | Soft Tissue Infections - economics | Male | Teicoplanin - therapeutic use | Osteomyelitis - drug therapy | Prosthesis-Related Infections - drug therapy | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Staphylococcal Skin Infections - drug therapy | Prosthesis-Related Infections - economics | Prosthesis-Related Infections - microbiology | Enterococcus - isolation & purification | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Soft Tissue Infections - drug therapy | Teicoplanin - analogs & derivatives | Catheter-Related Infections - economics | Osteomyelitis - economics | Methicillin-Resistant Staphylococcus aureus - drug effects | Catheter-Related Infections - drug therapy | Spain | Teicoplanin - adverse effects | Soft Tissue Infections - microbiology | Osteomyelitis - microbiology | Catheter-Related Infections - microbiology | Cost-Benefit Analysis | Aged | Enterococcus - drug effects | Methicillin-Resistant Staphylococcus aureus - isolation & purification
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 02/2018, Volume 14, Issue 2, pp. 197 - 206
Introduction: Acute bacterial skin and skin structure infections (ABSSIs), defined as a bacterial infection of the skin with a lesion size area of at least 75... 
antibiotic | Dalbavancin | skin infections | MRSA | ABSSIs | SOFT-TISSUE INFECTIONS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ONCE-WEEKLY DALBAVANCIN | WORLDWIDE COLLECTION | RESISTANT STAPHYLOCOCCUS-AUREUS | COMPARATOR AGENTS | ACUTE BACTERIAL SKIN | THERAPY | GRAM-POSITIVE INFECTIONS | SURVEILLANCE PROGRAM | LIPOGLYCOPEPTIDE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Index Medicus
Journal Article